RxDoctor Payments Data

David Kim, MD

Internal Medicine · New York, NYNPI 1558445395

Payments from drug & device makers

$834in general payments, 2019–2025

Across 19 payments — averaging $43.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Suvon Surgical LLC$355
  • Acumed LLC$190
  • Johnson & Johnson$97
  • Gilead$48
  • AbbVie$47
  • Incyte Corporation$28
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$82299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$834 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$82,621
Medicare patients
228
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala101$464,541
OdefseyEmtricitab/Rilpiviri/Tenof Ala39$172,280
TivicayDolutegravir Sodium63$157,050
TriumeqAbacavir/Dolutegravir/Lamivudi34$127,166
DescovyEmtricitabine/Tenofov Alafenam51$119,040
IsentressRaltegravir Potassium27$52,011
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$44,531
EdurantRilpivirine Hcl25$39,222
PrezistaDarunavir14$28,308
Maraviroc20$23,133
MounjaroTirzepatide18$20,689
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)16$3,606
Ritonavir11$3,130
Rosuvastatin Calcium212$2,387
Testosterone22$2,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$48$628,112165 claims
Viiv Healthcare CompanyTivicay, Triumeq$17$284,21797 claims
Lilly USA, LLCMounjaro$12$20,68918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →